Sqz Biotechnologies Company · OTC:SQZB
Sqz Biotechnologies — Investor Day (May 2022)
23 slides from Sqz Biotechnologies's investor day presentation, May 19, 2022
Slide 1: R&D Investor Event
S@ZBICTECH e OTECH PRESENTS R&D Investor Event May 19, 2022
Slide 2: Forward Looking Statements and Legal Disclaimers
Forward Looking Statements and Legal Disclaimers ‘This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained inthis presentation that do not relate to matters of historical fact should be considered forwa
Slide 3: Agenda
Item Welcome & Introduction sto Agenda Speaker(s) Armon Sharei, Ph.D., Chief Executive Officer and Founder Point-of-Care Cell Therapy Manufacturing Howard Bernstein, M.D., Ph.D., Chief Scientific Officer Maisam Dadgar, Head of Engineering Present & Future State of Cell Engineering Klavs F. Jensen, P
Slide 4: SQZ Biotech: Unlocking the Full Potential of Cell Therapies
SQZ Biotech: Unlocking the Full Potential of Cell Therapies ep & e or a© Investment Proprietary technology @ © Differentiated cell engineering capabilites with demonstrated precinical flexibility to deliver multiple material classes to diverse array of cell types * Safety data presents an opportunit
Slide 5: Diverse Pipeline Spanning Multiple Indications Across Broad Disease Areas
Diverse Pipeline Spanning Multiple Indications Across Broad Disease Areas CELL SOURCE PLATFORM. vane INDICATION PRE-CLINICAL PHASE 1/2 @ B,T,NK, monocytes Head & Neck, Cervical, Anal \ + —— Peptides other Solid Tumors 3 oe B, 7; NK, monocytes. Head & Neck, Cervical, Anal 2 saz* eAapcs Ascher Other S
Slide 6: Point-of-Care Manufacturing System
S@ZBIOTECH e TECH PRESENTS Point-of-Care Manufacturing System May 19, 2022
Slide 7: Today's Presenters
Today’s Presenters @ SQZ Biotechnologies—Point-of-Care System ® Howard Bernstein, M.D., Ph.D. Maisam Dadgar, M.S., M.B.A. Chief Scientific Officer Head of Engineering
Slide 8: An Introduction to the Primary Approaches of Cell Therapy
An Introduction to the Primary Approaches of Cell Therapy Autologous Cell Therapies Allogeneic Cell Therapies $2413 days vein-to-vein r= 12 days enrollment to infusion a go4] mewn hay of rowmnrrcotnonne fll) ©, ce iw | Key Characteristics: Key Characteristics: * Ex vivo cell cultivation and expansio
Slide 9: Proprietary Cell Squeeze Technology Enables Differentiated Capabilities
Proprietary Cell Squeeze® Technology Enables Differentiated Capabilities Cells and target cargo Cell membranes are Membranes together in suspension temporarily disrupted reseal Cells are squeezed through ‘Target cargo enters the SQZ° chip at high speeds cytosol of the cells | | to Robust across +) P
Slide 10: Cell Squeeze Approach Creates Improved Manufacturing Process and Patient Experience
Cell Squeeze® Approach Creates Improved Manufacturing Process and Patient Experience Current Cell Therapy Manufacturing fr on Patient $02 Process Cand Batch Leukapheresis <24-hours Release “pale "1 wok KEY HIGHLIGHTS MANUFACTURING STATISTICS $QZ® Manufacturing SQZ-PMBC-HPV-101 Trial + Therapeutic ap
Slide 11: Current Manufacturing Process is Rapid (<24 hours) but There is Still Room to Streamline
Current Manufacturing Process is Rapid (<24 hours) but There is Still Room to Streamline Current SQZ® Manufacturing Process 5 =
Slide 12: Transitioning to the Future for SQZ Manufacturing
Transitioning to the Future for SQZ® Manufacturing How do we go from here... i ee is | come a C= ee <a eon aay Same day production Potential on-site manufacturing without a clean room, Could enable much broader accessibility ua
Slide 13: SQZ Point-of-Care Manufacturing System
Slide 14: SQZ Point-of-Care: Condensing Commercial-Grade Manufacturing into a Single, Closed System
SQ2Z° Point-of-Care: Condensing Commercial-Grade Manufacturing into a Single, Closed System $QZ® POC Features and Benefits + End-to-end manufacturing condensed into a single, fully-closed processing environment + Customizable system and software for current manufacturing needs and future use-cases +
Slide 15: Significant Improvement to SQZ Manufacturing Time and Operator Hours on Point-of-Care
Significant Improvement to SQZ® Manufacturing Time and Operator Hours on Point-of-Care $QZ°® Point-of-Care System’s Per Batch Statistics Per Batch Statistics Current Process POC System ‘Average Processing Time 12hrs 45 mins 5 hrs 45 mins Required operator hours 150 15 Average yield @ highest dose 9
Slide 16: Testing and Validation of SQZ Point-of-Care for Clinical-Readiness
Testing and Validation of SQZ® Point-of-Care for Clinical-Readiness Implementation-readiness Manufacturing clinical batches + Optimize automation capabilities * First use-case is planned for TAC Celiac disease: * Develop further functions and capabilities Intended IND in the first half of 2023 + Sim
Slide 17: Potentially Powerful Long-Term Implications for SQZ Point-of-Care System
Potentially Powerful Long-Term Implications for SQZ® Point-of-Care System Same Day Production * Same day production inclusive of manufacturing, QC and batch release * Potential for <24-hour vein-to-vein for patients On-Site Manufacturing * Decentralized manufacturing in hospital / at treatment facil
Slide 18: Present & Future State of Cell Engineering
2 SQZ BIOTECH PRESENTS Present & Future State of Cell Engineering May 19, 2022
Slide 19: Broaden Therapeutic Possibilities Through Multi-Dimensional Cell Engineering
Broaden Therapeutic Possibilities Through Multi-Dimensional Cell Engineering mensional Cell Engineering in a Single Step What can the future of cell therapies look like? aaae Abilityto modulate or modify almost Add x 4 any therapeutically relevant function SUSE. Flexibility across cell types Upregul
Slide 20: Overcoming Barriers to Commercial Viability & Unleashing the Potential of Cell Therapies
Overcoming Barriers to Commercial Viability & Unleashing the Potential of Cell Therapies CAR-T Cell Allogeneic CAR CRISPR HSCs r< @ oS wAoMown — ure @ — ees © cere soma © tseng scat gone With SQZ® POC, there is potential to make autologous cell therapy as accessible as off- Enhanced APCs anes 7 ‘CEL
Slide 21: Present & Future State of Cell Engineering
2 SQZ BIOTECH PRESENTS Present & Future State of Cell Engineering May 19, 2022
Slide 22: Today's Panelists
Today’s Panelists @r Present & Future State of Cell Engineering VW 2 © @ © Robert S. Langer, Sc.D Klavs F. Jensen, Ph.D. Armon Sharei, Ph.D. Mike Huckman Scientific Advisory Board Member and Chief Executive Officer and of Real Chemistry Board Member and SQZ Biotech Founder QZ Biotech Founder and for
Slide 23: Present & Future State of Cell Engineering
2 SQZ BIOTECH PRESENTS Present & Future State of Cell Engineering May 19, 2022